サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：アニマルバイオテクノロジーの世界市場-2022-2029
市場調査レポート
商品コード
1129273

アニマルバイオテクノロジーの世界市場-2022-2029

Global Animal Biotechnology Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
アニマルバイオテクノロジーの世界市場-2022-2029
出版日: 2022年09月29日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

遺伝子工学の最近の進歩が市場成長の原動力になると予想されます。

近年の遺伝子工学の研究開発により、家畜におけるバイオテクノロジーの研究・応用の領域が広がっています。牛や鶏などの食用に飼育される動物は、肉や乳の中に高品質のタンパク質、必須アミノ酸、ミネラル、脂肪、吸収しやすいビタミン、微量の炭水化物、その他の生物活性物質を含んでいます。畜産業界では、動物の福祉と健康の向上、繁殖力の強化、動物から得られる製品の栄養的品質と安全性の向上のために、バイオテクノロジーが品種開発の促進に活用されています。人工授精、体外受精、体細胞核移植など、さまざまなバイオテクノロジー技術により、動物の繁殖力が向上しています。例えば、DNAマーカーを利用して動物の遺伝的特徴を明らかにし、その能力を予測することは、アニマルバイオテクノロジーにおいて有用です。マーカーアシスト選抜は、興味深い特徴の遺伝的決定因子を間接的に選抜する技術です。多くの形質は複数の遺伝子座に支配されており、それぞれの遺伝子座は量的形質座と呼ばれ、形質の変動に寄与しています。生産者は、胚に有意な量的特性遺伝子座が見つかった場合、胚を移植するか廃棄するかの選択肢を与えられることがあります。遺伝子または目的属性に強く関連する遺伝マーカーだけが、実際の育種の成功を保証することができます。

さらに、組み換えDNA技術も、rDNAと呼ばれる組み換えDNA分子を宿主生物に挿入することで、動物にとって有利な独自の遺伝子融合を作り出すことができる方法です。DNAワクチンは、遺伝子の多数のコピーの生産や、抗生物質耐性などの新しい形質を付与するために他の種に外来遺伝子を挿入し、動物ワクチンを生産することができるため、強力で長期にわたる細胞性免疫応答を引き出すことができます。したがって、上記の記述から、予測期間中に市場が牽引されることが予想されます。

制約事項

アニマルバイオテクノロジー製品のコスト高、アニマルバイオテクノロジー製品に関連する倫理的懸念、診断テストを行う熟練した専門家の不足などが、予測期間中に市場が阻害されると予想されるいくつかの要因です。

産業分析

アニマルバイオテクノロジー市場は、ポーターファイブフォース、サプライチェーン、価格分析、規制当局の承認など、様々な業界要因に基づく市場の詳細な分析を提供します。

COVID-19の影響分析

COVID-19のパンデミックは、市場に中程度の影響を及ぼしています。コロナウイルスの大流行により、バイオテクノロジー研究の潜在的な利点と落とし穴がクローズアップされています。こうした研究は、病気と闘うための医療措置の開発や、より健康な作物や家畜の開発に利用できる一方で、生物兵器の製造に利用される可能性もあるのです。世界中の研究者がパンデミックと積極的に戦っています。彼らは、安価な診断薬の開発、現在の抗ウイルス剤の再利用、新薬の発見、確実で効率的なワクチン接種の製造などの技術を駆使しています。

さらに、バイオテクノロジーによって、蚊の駆除などのために意図的に環境に放出することができる遺伝子組換え生物も製造することができます。例えば、CRISPR（Clustered regularly interspaced short palindromic repeats）やCas9（CRISPR-Associated protein 9）などのゲノムエンジニアリング技術の発展により、遺伝子ドライブの作成が可能になっています。この方法を用いると、数世代にわたって、希望する遺伝子改変を集団全体に素早く広げることができます。この技術により、マラリアやデング熱などの媒介となるヒトの病気を、これらの病気を引き起こす寄生虫に対する耐性を蚊に持たせるか、病気を媒介する蚊の個体群を完全に一掃することで治療することができます。一方、中堅・中小企業では、パンデミックによる動物病院の受診制限のため、課題がありました。したがって、パンデミックによってサプライチェーンが遮断されているのです。このように、COVID-19のパンデミックは市場に影響を及ぼしています。しかし、予測期間には、状況は徐々に改善されると予想されます。

世界のアニマルバイオテクノロジー市場レポートは、約45+市場データテーブル、40+図と180ページへのアクセスを提供するであろう。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

  • 市場影響要因
    • 促進要因
      • 遺伝子工学の進歩が市場成長の原動力となる見込み
    • 抑制要因
      • アニマルバイオテクノロジー製品の高コストが、予測期間中に阻害されると予想されます。
    • 市場機会
    • 影響分析

第5章 産業分析

  • ポーターの5つの力
  • アンメットニーズ
  • サプライチェーン
  • プライシング分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 動物タイプ別

  • 家畜
    • 魚類
    • 家禽類
    • 豚
    • 牛
    • 羊・ヤギ
    • その他
  • コンパニオン
      • イヌ
      • ネコ科動物
      • 馬
      • 水生動物
      • 鳥類
      • その他

第8章 製品タイプ別

  • 薬物
  • 予防接種
  • 診断用検査薬
  • 遺伝子・生殖関連製品
  • その他

第9章 アプリケーション別

  • 動物疾病の診断
  • 動物疾病の治療
  • 動物の予防医療
  • 医薬品開発
  • その他

第10章 エンドユーザー別

  • 動物病院・クリニック
  • ラボラトリー
  • 社内検査
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第13章 企業プロファイル

  • Boehringer Ingelheim GmbH
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Merck & Co.,Inc.
  • Virbac
  • Elanco
  • Zoetis
  • Biogenesis Bago
  • Idexx Laboratories
  • Heska Corporation
  • Indian Immunologicals Ltd.
  • HESTER BIOSCIENCES LIMITED

第14章 アニマルバイオテクノロジーの世界市場-DataM

目次
Product Code: DMBT5846

Market Overview

Animal Biotechnology Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of YY % during the forecast period (2022-2029).

Animal biotechnology refers to using engineering, science, and technology to modify and improve living organisms such as animals. Animal biotechnology can also be further explained as part of biotechnology, where molecular biotechnology techniques are used to genetically manipulate or modify the genome of various animals to improve their suitability for various applications such as pharmaceutical, industrial or agricultural applications. In the same case, animal biotechnology uses multiple methods to diagnose the various diseases in animals, allow the treatment of these diseases through multiple therapeutic options and the development of veterinary drugs, and the preventive care of animals through veterinary vaccines. The vaccination process is a highly effective and crucial tool for preventing animal diseases and promoting animal health and welfare, safe food production and public health.

Market Dynamics

Recent advances in genetic engineering are expected to drive market growth.

Recent developments in genetic engineering have widened the area of biotechnology research and application in farm animals. Animals raised for food, such as cattle and poultry, provide high-quality protein, essential amino acids, minerals, fats, easily absorbed vitamins, trace amounts of carbohydrates, and other bioactive substances in their meat and milk. In the livestock industry, biotechnology is being used to accelerate breed development for greater animal welfare and health, increased reproduction, and improved nutritional quality and safety of products obtained from animals. Through a range of biotechnological techniques, such as artificial insemination, in-vitro fertilization, and somatic cell nuclear transfer, animal breeding stock is thus improved. For instance, using DNA markers to describe an animal's genetic make-up and predict its performance is useful in animal biotechnology. Marker-assisted selection is a technique for indirectly selecting a genetic determinant of an interesting feature. Many traits are governed by multiple genetic loci, each of which is referred to as a quantitative trait locus and contributes to the trait's variation. The producer may be given the option of transferring or discarding the embryo if significant quantitative characteristic loci are found in the embryo. Only genetic markers strongly related to the genes or objective attributes can ensure successful breeding in practice.

Additionally, recombinant DNA technology is another method that allows the creation of unique genetic fusions advantageous to animals by inserting a recombined DNA molecule known as rDNA into a host organism. DNA vaccines can elicit potent, long-lasting cellular immune responses because it enables the production of numerous copies of genes and the insertion of foreign genes into other species to impart new traits like antibiotic resistance and the production of animal vaccines. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

The high cost of animal biotechnology products, ethical concerns related to animal biotechnology products and lack of skilled professionals to perform diagnostic tests are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The animal biotechnology market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain, pricing analysis, regulatory approvals etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted the market. The coronavirus pandemic has brought biotechnology research's potential benefits and pitfalls into focus. Although such research can be used to develop medical countermeasures to combat disease and to develop healthier crops and livestock, it can also be used to create biological weapons. Researchers from all across the world are aggressively battling the pandemic. They've utilized several technologies to develop affordable diagnostics, repurpose current antivirals, find novel medicines, and manufacture certain and efficient vaccinations.

Additionally, genetically modified organisms that can be purposefully released into the environment for things like mosquito control can be made via biotechnology. For instance, developments in genome engineering technologies, like clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9), have made it possible to create gene drives. This method enables desired genetic alterations to spread quickly throughout a population over several generations. This technique can cure vector-borne human diseases such as malaria and dengue fever by either making mosquitoes resistant to the parasites that cause these diseases or completely wiping out disease-carrying mosquito populations. In contrast, medium- and small-sized enterprises had challenges due to the pandemic's restrictions on veterinary clinic visits. Therefore, the pandemic is interrupting the supply chain. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Vaccinations segment is expected to hold the largest market share in animal biotechnology market.

The vaccinations segment accounted for the largest market share in 2021. The segment is benefited from the rising incidence of animal diseases, which naturally spread from animals to humans through consumption of contaminated food and water or direct contact with plagued individuals. Animal illness burden can be decreased through vaccination, which is also a key component of disease prevention and control. Moreover, new vaccine manufacturing techniques have emerged due to advances in technology, medicine, and basic scientific fields like immunology, molecular biology, microbiology, and biochemistry. The application of newer vaccination theories has been aided by genetic engineering, proteomics, and other cutting-edge technologies, leading to the discovery of new ruminant vaccines and the improvement of current ones. The next generation of vaccinations, which are being examined as potential alternatives to traditional immunizations, include subunit, recombinant, DNA, and vector.

Additionally, there are increasing vaccine launches for animals. For instance, Boehringer Ingelheim India introduced VAXXITEK HVT+IBD, a vaccine for poultry, in May 2021. All varieties of producing hens, including broiler, layer, and breeder chickens, are guaranteed lifelong protection by a novel recombinant vaccine called VAXXITEK HVT+IBD. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global animal biotechnology market

In 2021, North American animal biotechnology accounted for the highest revenue share in the global market. The increasing prevalence of zoonotic diseases, advances in genetic engineering in animals, and increasing initiatives and campaigns to promote animal health in the region are driving the market in the forecast period. For instance, according to Dr. Mark Walton, Chief Technology Officer at AquaBounty Technologies, AquAdvantage Salmon (AAS) presents several opportunities for addressing the impending fish shortage and developing a variety of nutrient-rich foods. According to Dr. Walton, AAS has faster development and improved feed efficiency, so it requires less time in water and feeds to get a kilo of proteins. The scientist added that AAS genetics is crucial to the system's profitability and that the AquAdvantage system is witnessing a significant rise in investment. The scientist asserted that the spread of salmon farming in recirculating aquaculture systems on land in the US and internationally would be significantly aided by AquAdvantage.

Furthermore, the Canadian Agricultural Partnership will start contributing up to $4 million in January 2021 to give farmers better access to veterinary services when and when they need them. To enable a collaborative and coordinated approach to transform technologies in the field of veterinary vaccines, biologicals, and diagnostics, TRPVB is a cooperation initiative between the Department of Biotechnology, India, and TANUVAS-Chennai. Therefore, it has increased the demand for animal biotechnology in the region. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the animal biotechnology market are Boehringer Ingelheim GmbH, Merck & Co.,Inc., Virbac, Elanco, Zoetis, Biogenesis Bago, Idexx Laboratories, Heska Corporation, Indian Immunologicals Ltd. and HESTER BIOSCIENCES LIMITED.

Boehringer Ingelheim GmbH:

Overview:

Boehringer Ingelheim is one of Germany's leading contract manufacturers of biopharmaceuticals based on cell cultures and microorganisms. The company is divided into three business areas: human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. Moreover, in the animal health sector, Boehringer Ingelheim is one of the world's leading suppliers of vaccines, therapeutics and preventive products that protect animals from disease and pain. In addition, the company achieved net sales of around 4.3 billion euros in the animal health sector in 2021, corresponding to 21 percent of the total net sales. The company's integrated product portfolio includes more than 200 products for dogs, cats, horses, pigs, cattle and poultry. The parasiticides NEXGARD and FRONTLINE for dogs and cats, HEARTGARD for dogs, and the pig vaccines INGELVAC CIRCOFLEX/ FLEXBOMBO are among the best-known brands. Furthermore, the company has an established global animal health innovation network with 18 R&D sites worldwide. The focus is innovative vaccines and parasiticides to protect livestock and companion animals and therapeutics for treating chronic diseases and other debilitating conditions.

Product Portfolio:

Ingelvac PRRS MLV: Ingelvac PRRS MLV is a modified live PRRS vaccine that is safe in pigs, gilts, and sows at all stages of production in PRRS-positive herds. It offers cross-protection against heterologous challenges; (including the Lelystad virus) and has significantly reduced reproductive disorders and respiratory disease due to the PRRS virus.

  • Trusted and field-proven
  • Cost-effective
  • Unique in its ability to be used in pigs (3 weeks or older), gilts, and sows at ANY stage of production
  • Available in three convenient sizes (10, 50, and 250 doses)

The global animal biotechnology market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Recent advances in genetic engineering are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The high cost of animal biotechnology products is expected to get hampered in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply Chain
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Animal Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 7.1.2. Market Attractiveness Index, By Animal Type Segment
  • 7.2. Livestock*
      • 7.2.1.1. Fish
      • 7.2.1.2. Poultry
      • 7.2.1.3. Swine
      • 7.2.1.4. Cattle
      • 7.2.1.5. Sheep & Goats
      • 7.2.1.6. Others
      • 7.2.1.6.1. Introduction
      • 7.2.1.6.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Companion
      • 7.3.1.1. Canine
      • 7.3.1.2. Feline
      • 7.3.1.3. Equine
      • 7.3.1.4. Aquatic
      • 7.3.1.5. Avian
      • 7.3.1.6. Others

8. By Product Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 8.1.2. Market Attractiveness Index, By Product Type Segment
  • 8.2. Drugs*
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Vaccinations
  • 8.4. Diagnostic Tests
  • 8.5. Genetic & Reproductive Products
  • 8.6. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application Segment
  • 9.2. Diagnosis of Animal Diseases*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Treatment of Animal Diseases
  • 9.4. Preventive Care of Animals
  • 9.5. Drug Development
  • 9.6. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Veterinary Hospitals & Clinics*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Laboratories
  • 10.4. In-house Testing
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Boehringer Ingelheim GmbH*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Merck & Co.,Inc.
  • 13.3. Virbac
  • 13.4. Elanco
  • 13.5. Zoetis
  • 13.6. Biogenesis Bago
  • 13.7. Idexx Laboratories
  • 13.8. Heska Corporation
  • 13.9. Indian Immunologicals Ltd.
  • 13.10. HESTER BIOSCIENCES LIMITED

LIST NOT EXHAUSTIVE

14. Global Animal Biotechnology Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us